Cargando…

Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia

BACKGROUND AND AIMS: Hypertriglyceridemia is a common feature of metabolic syndrome (MetS), as well as of non-alcoholic fatty liver disease (NAFLD), which is considered the hepatic manifestation of MetS. Fat accumulation in hepatocytes may alter mitochondrial homeostasis predisposing to advanced liv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meroni, Marica, Longo, Miriam, Paolini, Erika, Tria, Giada, Ripolone, Michela, Napoli, Laura, Moggio, Maurizio, Fracanzani, Anna Ludovica, Dongiovanni, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Nutrition
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521372/ https://www.ncbi.nlm.nih.gov/pubmed/36185699 http://dx.doi.org/10.3389/fnut.2022.967899

Ejemplares similares

The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
por: Paolini, Erika, et al.
Publicado: (2023)

Genetics Is of the Essence to Face NAFLD
por: Meroni, Marica, et al.
Publicado: (2021)

Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
por: Meroni, Marica, et al.
Publicado: (2021)

α-Lipoic Acid Improves Hepatic Metabolic Dysfunctions in Acute Intermittent Porphyria: A Proof-of-Concept Study
por: Longo, Miriam, et al.
Publicado: (2021)

miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis
por: Dongiovanni, Paola, et al.
Publicado: (2018)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Dongiovanni, Paola, et al.
Publicado: (2021)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution
por: Longo, Miriam, et al.
Publicado: (2022)

MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD
por: Meroni, Marica, et al.
Publicado: (2020)

mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance
por: Meroni, Marica, et al.
Publicado: (2019)

The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies
por: Meroni, Marica, et al.
Publicado: (2019)

The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
por: Panera, Nadia, et al.
Publicado: (2021)

The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients
por: Meroni, Marica, et al.
Publicado: (2021)

PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease
por: Lombardi, Rosa, et al.
Publicado: (2022)

Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
por: Cespiati, Annalisa, et al.
Publicado: (2022)

An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians
por: Cespiati, Annalisa, et al.
Publicado: (2023)

Alcohol or Gut Microbiota: Who Is the Guilty?
por: Meroni, Marica, et al.
Publicado: (2019)

Genetic and Epigenetic Modifiers of Alcoholic Liver Disease
por: Meroni, Marica, et al.
Publicado: (2018)

Nutrition and Genetics in NAFLD: The Perfect Binomium
por: Meroni, Marica, et al.
Publicado: (2020)

The Non-Invasive Assessment of Circulating D-Loop and mt-ccf Levels Opens an Intriguing Spyhole into Novel Approaches for the Tricky Diagnosis of NASH
por: Paolini, Erika, et al.
Publicado: (2023)

MERRF Mutation A8344G in a Four-Generation Family without Central Nervous System Involvement: Clinical and Molecular Characterization
por: Ripolone, Michela, et al.
Publicado: (2023)

The effect of omega-3 fatty acids and its combination with statins on lipid profile in patients with hypertriglyceridemia: A systematic review and meta-analysis of randomized controlled trials
por: Yang, Yunjiao, et al.
Publicado: (2022)

Bioactive Compounds for the Management of Hypertriglyceridemia: Evidence From Clinical Trials and Putative Action Targets
por: Schiano, Elisabetta, et al.
Publicado: (2020)

TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
por: Longo, Miriam, et al.
Publicado: (2021)

Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes
por: Meroni, Marica, et al.
Publicado: (2020)

PNPLA3 rs738409 Genetic Variant Inversely Correlates with Platelet Count, Thereby Affecting the Performance of Noninvasive Scores of Hepatic Fibrosis
por: Meroni, Marica, et al.
Publicado: (2023)

One Month of Classic Therapeutic Ketogenic Diet Decreases Short Chain Fatty Acids Production in Epileptic Patients
por: Ferraris, Cinzia, et al.
Publicado: (2021)

Evidence or no evidence for essential fatty acids in the treatment of autism spectrum disorders?
por: Pancheva, Rouzha Zlatanova, et al.
Publicado: (2023)

Daily Intake of a Phaseolus vulgaris L. Snack Bar Attenuates Hypertriglyceridemia and Improves Lipid Metabolism-Associated Plasma Proteins in Mexican Women: A Randomized Clinical Trial
por: Ramírez-Jiménez, Aurea K., et al.
Publicado: (2022)

Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease
por: Lombardi, Rosa, et al.
Publicado: (2020)

From Environment to Genome and Back: A Lesson from HFE Mutations
por: Rametta, Raffaela, et al.
Publicado: (2020)

The Genetic Spectrum of Familial Hypertriglyceridemia in Oman
por: Al-Waili, Khalid, et al.
Publicado: (2022)

A Brief Journey into the History of and Future Sources and Uses of Fatty Acids
por: Cerone, Michela, et al.
Publicado: (2021)

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease
por: Pelusi, Serena, et al.
Publicado: (2016)

Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study
por: Dongiovanni, Paola, et al.
Publicado: (2010)

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
por: Pelusi, Serena, et al.
Publicado: (2019)

Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin
por: Pisano, Giuseppina, et al.
Publicado: (2016)

The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls
por: Valenti, Luca, et al.
Publicado: (2012)

Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease
por: Dongiovanni, Paola, et al.
Publicado: (2018)

Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease
por: Fracanzani, Anna Ludovica, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i5lgd6big2pajen537c208lfd4